Gene · 466
Papers2,331
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 2,331
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. | Brain Pathol | 2022 | 34821426 | PubTator, text mining | PubMed |
| Chemical Therapies for Congenital Disorders of Glycosylation. | ACS Chem Biol | 2022 | 34788024 | PubTator, text mining | PubMed |
| The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. | Clin Cancer Res | 2022 | 34753780 | PubTator, text mining | PubMed |
| Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas. | Clin Cancer Res | 2022 | 34716194 | PubTator, text mining | PubMed |
| Clear cell carcinoma: a comprehensive literature review of 254 cases. | Int J Oral Maxillofac Surg | 2022 | 34686398 | PubTator, text mining | PubMed |
| Epigenetic clock and methylation studies in vervet monkeys. | Geroscience | 2022 | 34591235 | PubTator, text mining | PubMed |
| Regulation of Neurogenesis and Neuronal Differentiation by Natural Compounds. | Curr Stem Cell Res Ther | 2022 | 34493197 | PubTator, text mining | PubMed |
| Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. | Cancer Discov | 2022 | 34479871 | PubTator, text mining | PubMed |
An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts. | Brain Pathol | 2022 | 34314078 | PubTator, text mining | PubMed |
| Clear Cell Carcinoma in the Oral Cavity with Three Novel Types of EWSR1-ATF1 Translocation: A Case Report. | Head Neck Pathol | 2022 | 34251595 | PubTator, text mining | PubMed |
| Intra-abdominal EWSR1/FUS-CREM-rearranged malignant epithelioid neoplasms: two cases of an emerging aggressive entity with emphasis on misleading immunophenotype. | Virchows Arch | 2022 | 34228212 | PubTator, text mining | PubMed |
| Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. | Alzheimers Dement | 2022 | 34223696 | PubTator, text mining | PubMed |
| Cytokeratin-positive Malignant Tumor in the Abdomen With EWSR1/FUS-CREB Fusion: A Clinicopathologic Study of 8 Cases. | Am J Surg Pathol | 2022 | 34049318 | PubTator, text mining | PubMed |
| Circ_0000745 Promotes the Progression of Cervical Cancer by Regulating miR-409-3p/ATF1 Axis. | Cancer Biother Radiopharm | 2022 | 32644859 | PubTator, text mining | PubMed |
| BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin. | Cancer Res Commun | 2021 | 36860287 | PubTator, text mining | PubMed |
| Intracranial temporal bone angiomatoid fibrous histiocytoma: illustrative case. | J Neurosurg Case Lessons | 2021 | 36034510 | PubTator, text mining | PubMed |
| Mitochondrial-Derived Peptides in Diabetes and Its Complications. | Front Endocrinol (Lausanne) | 2021 | 35185787 | PubTator, text mining | PubMed |
| Cell Fusion-Related Proteins and Signaling Pathways, and Their Roles in the Development and Progression of Cancer. | Front Cell Dev Biol | 2021 | 35178400 | PubTator, text mining | PubMed |
| Deletion of Wild-type p53 Facilitates Bone Metastatic Function by Blocking the AIP4 Mediated Ligand-Induced Degradation of CXCR4. | Front Pharmacol | 2021 | 35177982 | PubTator, text mining | PubMed |
| Heme in Cardiovascular Diseases: A Ubiquitous Dangerous Molecule Worthy of Vigilance. | Front Cell Dev Biol | 2021 | 35127704 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/466/papers?page=27